aluates Reports

$ 0.0

Automative

Global Biosimilar Insulin Glargine Market Research Report 2025

Published Date: July 2025

Report Code: QYRE-Auto-15W7568

Global Biosimilar Insulin Glargine Market Insights Forecast to 2028

BUY CHAPTERS

Global Biosimilar Insulin Glargine Market Research Report 2025

Code: QYRE-Auto-15W7568

Report

July 2025

Pages:86

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Eli Lilly

Gan & Lee

Tonghua Dongbao

United Laboratory

Geropharm

Biocon Ltd.

WOCKHARDT

Biosimilar Insulin Glargine Market Size

The global market for Biosimilar Insulin Glargine was valued at US$ 2151 million in the year 2024 and is projected to reach a revised size of US$ 2602 million by 2031, growing at a CAGR of 2.8% during the forecast period.

Biosimilar Insulin Glargine Market

Insulin glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours. Insulin glargine is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Biosimilar Insulin Glargine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Insulin Glargine.

The Biosimilar Insulin Glargine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biosimilar Insulin Glargine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Biosimilar Insulin Glargine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Biosimilar Insulin Glargine Market Report

Report Metric	Details
Report Name	Biosimilar Insulin Glargine Market
Accounted market size in year	US$ 2151 million
Forecasted market size in 2031	US$ 2602 million
CAGR	2.8%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Pre-filled Cartridge
Segment by Application	Hospital Retail Pharmacy Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Eli Lilly, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon, Wockhardt
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biosimilar Insulin Glargine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biosimilar Insulin Glargine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Biosimilar Insulin Glargine Market growing?

Ans: The Biosimilar Insulin Glargine Market witnessing a CAGR of 2.8% during the forecast period 2025-2031.

What is the Biosimilar Insulin Glargine Market size in 2031?

Ans: The Biosimilar Insulin Glargine Market size in 2031 will be US$ 2602 million.

Who are the main players in the Biosimilar Insulin Glargine Market report?

Ans: The main players in the Biosimilar Insulin Glargine Market are Eli Lilly, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon, Wockhardt

What are the Application segmentation covered in the Biosimilar Insulin Glargine Market report?

Ans: The Applications covered in the Biosimilar Insulin Glargine Market report are Hospital, Retail Pharmacy, Others

What are the Type segmentation covered in the Biosimilar Insulin Glargine Market report?

Ans: The Types covered in the Biosimilar Insulin Glargine Market report are Pre-filled, Cartridge

Recommended Reports

Diabetes Therapeutics

Biosimilars & Biologics

Metabolic & Chronic

1 Biosimilar Insulin Glargine Market Overview

1.1 Product Definition

1.2 Biosimilar Insulin Glargine by Type

1.2.1 Global Biosimilar Insulin Glargine Market Value Comparison by Type (2024 VS 2031)

1.2.2 Pre-filled

1.2.3 Cartridge

1.3 Biosimilar Insulin Glargine by Application

1.3.1 Global Biosimilar Insulin Glargine Market Value by Application (2024 VS 2031)

1.3.2 Hospital

1.3.3 Retail Pharmacy

1.3.4 Others

1.4 Global Biosimilar Insulin Glargine Market Size Estimates and Forecasts

1.4.1 Global Biosimilar Insulin Glargine Revenue 2020-2031

1.4.2 Global Biosimilar Insulin Glargine Sales 2020-2031

1.4.3 Global Biosimilar Insulin Glargine Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Biosimilar Insulin Glargine Market Competition by Manufacturers

2.1 Global Biosimilar Insulin Glargine Sales Market Share by Manufacturers (2020-2025)

2.2 Global Biosimilar Insulin Glargine Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Biosimilar Insulin Glargine Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Biosimilar Insulin Glargine, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Biosimilar Insulin Glargine, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Biosimilar Insulin Glargine, Product Type & Application

2.7 Global Key Manufacturers of Biosimilar Insulin Glargine, Date of Enter into This Industry

2.8 Global Biosimilar Insulin Glargine Market Competitive Situation and Trends

2.8.1 Global Biosimilar Insulin Glargine Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Biosimilar Insulin Glargine Players Market Share by Revenue

2.8.3 Global Biosimilar Insulin Glargine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Biosimilar Insulin Glargine Market Scenario by Region

3.1 Global Biosimilar Insulin Glargine Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Biosimilar Insulin Glargine Sales by Region: 2020-2031

3.2.1 Global Biosimilar Insulin Glargine Sales by Region: 2020-2025

3.2.2 Global Biosimilar Insulin Glargine Sales by Region: 2026-2031

3.3 Global Biosimilar Insulin Glargine Revenue by Region: 2020-2031

3.3.1 Global Biosimilar Insulin Glargine Revenue by Region: 2020-2025

3.3.2 Global Biosimilar Insulin Glargine Revenue by Region: 2026-2031

3.4 North America Biosimilar Insulin Glargine Market Facts & Figures by Country

3.4.1 North America Biosimilar Insulin Glargine Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Biosimilar Insulin Glargine Sales by Country (2020-2031)

3.4.3 North America Biosimilar Insulin Glargine Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Biosimilar Insulin Glargine Market Facts & Figures by Country

3.5.1 Europe Biosimilar Insulin Glargine Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Biosimilar Insulin Glargine Sales by Country (2020-2031)

3.5.3 Europe Biosimilar Insulin Glargine Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Biosimilar Insulin Glargine Market Facts & Figures by Region

3.6.1 Asia Pacific Biosimilar Insulin Glargine Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Biosimilar Insulin Glargine Sales by Region (2020-2031)

3.6.3 Asia Pacific Biosimilar Insulin Glargine Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Biosimilar Insulin Glargine Market Facts & Figures by Country

3.7.1 Latin America Biosimilar Insulin Glargine Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Biosimilar Insulin Glargine Sales by Country (2020-2031)

3.7.3 Latin America Biosimilar Insulin Glargine Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Biosimilar Insulin Glargine Market Facts & Figures by Country

3.8.1 Middle East and Africa Biosimilar Insulin Glargine Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Biosimilar Insulin Glargine Sales by Country (2020-2031)

3.8.3 Middle East and Africa Biosimilar Insulin Glargine Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Biosimilar Insulin Glargine Sales by Type (2020-2031)

4.1.1 Global Biosimilar Insulin Glargine Sales by Type (2020-2025)

4.1.2 Global Biosimilar Insulin Glargine Sales by Type (2026-2031)

4.1.3 Global Biosimilar Insulin Glargine Sales Market Share by Type (2020-2031)

4.2 Global Biosimilar Insulin Glargine Revenue by Type (2020-2031)

4.2.1 Global Biosimilar Insulin Glargine Revenue by Type (2020-2025)

4.2.2 Global Biosimilar Insulin Glargine Revenue by Type (2026-2031)

4.2.3 Global Biosimilar Insulin Glargine Revenue Market Share by Type (2020-2031)

4.3 Global Biosimilar Insulin Glargine Price by Type (2020-2031)

5 Segment by Application

5.1 Global Biosimilar Insulin Glargine Sales by Application (2020-2031)

5.1.1 Global Biosimilar Insulin Glargine Sales by Application (2020-2025)

5.1.2 Global Biosimilar Insulin Glargine Sales by Application (2026-2031)

5.1.3 Global Biosimilar Insulin Glargine Sales Market Share by Application (2020-2031)

5.2 Global Biosimilar Insulin Glargine Revenue by Application (2020-2031)

5.2.1 Global Biosimilar Insulin Glargine Revenue by Application (2020-2025)

5.2.2 Global Biosimilar Insulin Glargine Revenue by Application (2026-2031)

5.2.3 Global Biosimilar Insulin Glargine Revenue Market Share by Application (2020-2031)

5.3 Global Biosimilar Insulin Glargine Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Eli Lilly

6.1.1 Eli Lilly Company Information

6.1.2 Eli Lilly Description and Business Overview

6.1.3 Eli Lilly Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Eli Lilly Biosimilar Insulin Glargine Product Portfolio

6.1.5 Eli Lilly Recent Developments/Updates

6.2 Gan&Lee

6.2.1 Gan&Lee Company Information

6.2.2 Gan&Lee Description and Business Overview

6.2.3 Gan&Lee Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Gan&Lee Biosimilar Insulin Glargine Product Portfolio

6.2.5 Gan&Lee Recent Developments/Updates

6.3 Tonghua Dongbao

6.3.1 Tonghua Dongbao Company Information

6.3.2 Tonghua Dongbao Description and Business Overview

6.3.3 Tonghua Dongbao Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Tonghua Dongbao Biosimilar Insulin Glargine Product Portfolio

6.3.5 Tonghua Dongbao Recent Developments/Updates

6.4 United Laboratory

6.4.1 United Laboratory Company Information

6.4.2 United Laboratory Description and Business Overview

6.4.3 United Laboratory Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2020-2025)

6.4.4 United Laboratory Biosimilar Insulin Glargine Product Portfolio

6.4.5 United Laboratory Recent Developments/Updates

6.5 Geropharm

6.5.1 Geropharm Company Information

6.5.2 Geropharm Description and Business Overview

6.5.3 Geropharm Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Geropharm Biosimilar Insulin Glargine Product Portfolio

6.5.5 Geropharm Recent Developments/Updates

6.6 Biocon

6.6.1 Biocon Company Information

6.6.2 Biocon Description and Business Overview

6.6.3 Biocon Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Biocon Biosimilar Insulin Glargine Product Portfolio

6.6.5 Biocon Recent Developments/Updates

6.7 Wockhardt

6.7.1 Wockhardt Company Information

6.7.2 Wockhardt Description and Business Overview

6.7.3 Wockhardt Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Wockhardt Biosimilar Insulin Glargine Product Portfolio

6.7.5 Wockhardt Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Biosimilar Insulin Glargine Industry Chain Analysis

7.2 Biosimilar Insulin Glargine Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Biosimilar Insulin Glargine Production Mode & Process Analysis

7.4 Biosimilar Insulin Glargine Sales and Marketing

7.4.1 Biosimilar Insulin Glargine Sales Channels

7.4.2 Biosimilar Insulin Glargine Distributors

7.5 Biosimilar Insulin Glargine Customer Analysis

8 Biosimilar Insulin Glargine Market Dynamics

8.1 Biosimilar Insulin Glargine Industry Trends

8.2 Biosimilar Insulin Glargine Market Drivers

8.3 Biosimilar Insulin Glargine Market Challenges

8.4 Biosimilar Insulin Glargine Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Eli Lilly

Gan & Lee

Tonghua Dongbao

United Laboratory

Geropharm

Biocon Ltd.

WOCKHARDT

List of Tables

Table 1. Global Biosimilar Insulin Glargine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Biosimilar Insulin Glargine Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Biosimilar Insulin Glargine Market Competitive Situation by Manufacturers in 2024

Table 4. Global Biosimilar Insulin Glargine Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Biosimilar Insulin Glargine Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Biosimilar Insulin Glargine Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Biosimilar Insulin Glargine Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Biosimilar Insulin Glargine Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Biosimilar Insulin Glargine, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Biosimilar Insulin Glargine, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Biosimilar Insulin Glargine, Product Type & Application

Table 12. Global Key Manufacturers of Biosimilar Insulin Glargine, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Biosimilar Insulin Glargine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Insulin Glargine as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Biosimilar Insulin Glargine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Biosimilar Insulin Glargine Sales by Region (2020-2025) & (K Units)

Table 18. Global Biosimilar Insulin Glargine Sales Market Share by Region (2020-2025)

Table 19. Global Biosimilar Insulin Glargine Sales by Region (2026-2031) & (K Units)

Table 20. Global Biosimilar Insulin Glargine Sales Market Share by Region (2026-2031)

Table 21. Global Biosimilar Insulin Glargine Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Biosimilar Insulin Glargine Revenue Market Share by Region (2020-2025)

Table 23. Global Biosimilar Insulin Glargine Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Biosimilar Insulin Glargine Revenue Market Share by Region (2026-2031)

Table 25. North America Biosimilar Insulin Glargine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Biosimilar Insulin Glargine Sales by Country (2020-2025) & (K Units)

Table 27. North America Biosimilar Insulin Glargine Sales by Country (2026-2031) & (K Units)

Table 28. North America Biosimilar Insulin Glargine Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Biosimilar Insulin Glargine Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Biosimilar Insulin Glargine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Biosimilar Insulin Glargine Sales by Country (2020-2025) & (K Units)

Table 32. Europe Biosimilar Insulin Glargine Sales by Country (2026-2031) & (K Units)

Table 33. Europe Biosimilar Insulin Glargine Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Biosimilar Insulin Glargine Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Biosimilar Insulin Glargine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Biosimilar Insulin Glargine Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Biosimilar Insulin Glargine Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Biosimilar Insulin Glargine Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Biosimilar Insulin Glargine Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Biosimilar Insulin Glargine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Biosimilar Insulin Glargine Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Biosimilar Insulin Glargine Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Biosimilar Insulin Glargine Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Biosimilar Insulin Glargine Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Biosimilar Insulin Glargine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Biosimilar Insulin Glargine Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Biosimilar Insulin Glargine Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Biosimilar Insulin Glargine Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Biosimilar Insulin Glargine Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Biosimilar Insulin Glargine Sales (K Units) by Type (2020-2025)

Table 51. Global Biosimilar Insulin Glargine Sales (K Units) by Type (2026-2031)

Table 52. Global Biosimilar Insulin Glargine Sales Market Share by Type (2020-2025)

Table 53. Global Biosimilar Insulin Glargine Sales Market Share by Type (2026-2031)

Table 54. Global Biosimilar Insulin Glargine Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Biosimilar Insulin Glargine Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Biosimilar Insulin Glargine Revenue Market Share by Type (2020-2025)

Table 57. Global Biosimilar Insulin Glargine Revenue Market Share by Type (2026-2031)

Table 58. Global Biosimilar Insulin Glargine Price (US$/Unit) by Type (2020-2025)

Table 59. Global Biosimilar Insulin Glargine Price (US$/Unit) by Type (2026-2031)

Table 60. Global Biosimilar Insulin Glargine Sales (K Units) by Application (2020-2025)

Table 61. Global Biosimilar Insulin Glargine Sales (K Units) by Application (2026-2031)

Table 62. Global Biosimilar Insulin Glargine Sales Market Share by Application (2020-2025)

Table 63. Global Biosimilar Insulin Glargine Sales Market Share by Application (2026-2031)

Table 64. Global Biosimilar Insulin Glargine Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Biosimilar Insulin Glargine Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Biosimilar Insulin Glargine Revenue Market Share by Application (2020-2025)

Table 67. Global Biosimilar Insulin Glargine Revenue Market Share by Application (2026-2031)

Table 68. Global Biosimilar Insulin Glargine Price (US$/Unit) by Application (2020-2025)

Table 69. Global Biosimilar Insulin Glargine Price (US$/Unit) by Application (2026-2031)

Table 70. Eli Lilly Company Information

Table 71. Eli Lilly Description and Business Overview

Table 72. Eli Lilly Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Eli Lilly Biosimilar Insulin Glargine Product

Table 74. Eli Lilly Recent Developments/Updates

Table 75. Gan&Lee Company Information

Table 76. Gan&Lee Description and Business Overview

Table 77. Gan&Lee Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Gan&Lee Biosimilar Insulin Glargine Product

Table 79. Gan&Lee Recent Developments/Updates

Table 80. Tonghua Dongbao Company Information

Table 81. Tonghua Dongbao Description and Business Overview

Table 82. Tonghua Dongbao Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Tonghua Dongbao Biosimilar Insulin Glargine Product

Table 84. Tonghua Dongbao Recent Developments/Updates

Table 85. United Laboratory Company Information

Table 86. United Laboratory Description and Business Overview

Table 87. United Laboratory Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. United Laboratory Biosimilar Insulin Glargine Product

Table 89. United Laboratory Recent Developments/Updates

Table 90. Geropharm Company Information

Table 91. Geropharm Description and Business Overview

Table 92. Geropharm Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Geropharm Biosimilar Insulin Glargine Product

Table 94. Geropharm Recent Developments/Updates

Table 95. Biocon Company Information

Table 96. Biocon Description and Business Overview

Table 97. Biocon Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Biocon Biosimilar Insulin Glargine Product

Table 99. Biocon Recent Developments/Updates

Table 100. Wockhardt Company Information

Table 101. Wockhardt Description and Business Overview

Table 102. Wockhardt Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Wockhardt Biosimilar Insulin Glargine Product

Table 104. Wockhardt Recent Developments/Updates

Table 105. Key Raw Materials Lists

Table 106. Raw Materials Key Suppliers Lists

Table 107. Biosimilar Insulin Glargine Distributors List

Table 108. Biosimilar Insulin Glargine Customers List

Table 109. Biosimilar Insulin Glargine Market Trends

Table 110. Biosimilar Insulin Glargine Market Drivers

Table 111. Biosimilar Insulin Glargine Market Challenges

Table 112. Biosimilar Insulin Glargine Market Restraints

Table 113. Research Programs/Design for This Report

Table 114. Key Data Information from Secondary Sources

Table 115. Key Data Information from Primary Sources

Table 116. Authors List of This Report

List of Figures

Figure 1. Product Picture of Biosimilar Insulin Glargine

Figure 2. Global Biosimilar Insulin Glargine Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Biosimilar Insulin Glargine Market Share by Type: 2024 & 2031

Figure 4. Pre-filled Product Picture

Figure 5. Cartridge Product Picture

Figure 6. Global Biosimilar Insulin Glargine Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Biosimilar Insulin Glargine Market Share by Application: 2024 & 2031

Figure 8. Hospital

Figure 9. Retail Pharmacy

Figure 10. Others

Figure 11. Global Biosimilar Insulin Glargine Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global Biosimilar Insulin Glargine Market Size (2020-2031) & (US$ Million)

Figure 13. Global Biosimilar Insulin Glargine Sales (2020-2031) & (K Units)

Figure 14. Global Biosimilar Insulin Glargine Average Price (US$/Unit) & (2020-2031)

Figure 15. Biosimilar Insulin Glargine Report Years Considered

Figure 16. Biosimilar Insulin Glargine Sales Share by Manufacturers in 2024

Figure 17. Global Biosimilar Insulin Glargine Revenue Share by Manufacturers in 2024

Figure 18. Global 5 and 10 Largest Biosimilar Insulin Glargine Players: Market Share by Revenue in Biosimilar Insulin Glargine in 2024

Figure 19. Biosimilar Insulin Glargine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 20. Global Biosimilar Insulin Glargine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 21. North America Biosimilar Insulin Glargine Sales Market Share by Country (2020-2031)

Figure 22. North America Biosimilar Insulin Glargine Revenue Market Share by Country (2020-2031)

Figure 23. United States Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Canada Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Europe Biosimilar Insulin Glargine Sales Market Share by Country (2020-2031)

Figure 26. Europe Biosimilar Insulin Glargine Revenue Market Share by Country (2020-2031)

Figure 27. Germany Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. France Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. U.K. Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Italy Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Russia Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Asia Pacific Biosimilar Insulin Glargine Sales Market Share by Region (2020-2031)

Figure 33. Asia Pacific Biosimilar Insulin Glargine Revenue Market Share by Region (2020-2031)

Figure 34. China Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Japan Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. South Korea Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. India Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Australia Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. China Taiwan Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Indonesia Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Thailand Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Malaysia Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Latin America Biosimilar Insulin Glargine Sales Market Share by Country (2020-2031)

Figure 44. Latin America Biosimilar Insulin Glargine Revenue Market Share by Country (2020-2031)

Figure 45. Mexico Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Brazil Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Argentina Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Middle East and Africa Biosimilar Insulin Glargine Sales Market Share by Country (2020-2031)

Figure 49. Middle East and Africa Biosimilar Insulin Glargine Revenue Market Share by Country (2020-2031)

Figure 50. Turkey Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Saudi Arabia Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. UAE Biosimilar Insulin Glargine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Global Sales Market Share of Biosimilar Insulin Glargine by Type (2020-2031)

Figure 54. Global Revenue Market Share of Biosimilar Insulin Glargine by Type (2020-2031)

Figure 55. Global Biosimilar Insulin Glargine Price (US$/Unit) by Type (2020-2031)

Figure 56. Global Sales Market Share of Biosimilar Insulin Glargine by Application (2020-2031)

Figure 57. Global Revenue Market Share of Biosimilar Insulin Glargine by Application (2020-2031)

Figure 58. Global Biosimilar Insulin Glargine Price (US$/Unit) by Application (2020-2031)

Figure 59. Biosimilar Insulin Glargine Value Chain

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Long Acting Insulins Market Insights Forecast to 2030

Global Insulin Glargine and Lispro Market Research Report 2024

Basal Insulin Long Acting Insulin Market

Global Short acting Insulin Market Research Report 2024

Global Insulin Drugs for Diabetes Market Research Report 2024

Global Long Acting Insulin Analogue Market Research Report 2025

Global Insulin Glargine Injection Market Research Report 2024

Insulin Biologics and Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Rapid Acting Insulins Market Insights Forecast to 2030

Global Insulin Detemir Injection Market Research Report 2024

Biosimilar Insulin Market

Meglinitide Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Oral Insulin Market Research Report 2025

Global Insulin Storage Devices Market Research Report 2024

Global Mealtime Insulin Market Research Report 2024

Global Long acting GLP 1RA Market Research Report 2024

Global Ultra Long Acting Insulin Market Research Report 2025

Global Insulin Raw Material Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions